Aqueous two phase system microfluidic isolation and concentration of extracellular vesicles

水性两相系统微流体分离和细胞外囊泡浓缩

• 批准号: 561583-2021
• 负责人: Tsai, Scott
• 金额: $ 9.11万
• 依托单位: Ryerson University
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=724278
• 关键词: Aqueous; two; phase; system; microfluidic

This NSERC Idea to Innovation (I2I) grant is funding the development of a microfluidic platform technology that directly isolates and purifies extracellular vesicles (EVs) from bodily fluids, like whole blood and urine. This microfluidic approach results in EV concentrations that are several times higher than the concentrations achievable using the current gold-standard ultracentrifugation technique. Our approach combines the precision of microfluidics with the selective partitioning capability of aqueous two-phase system (ATPS) fluids, to isolate and purify EVs, and importantly, overcome the critical limitations of ultracentrifugation--namely, EV concentrations that are too low for applications, co-isolation of impurities, and EV damage. The key innovations of our technology are the marriage of microfluidics and an in-house optimized ATPS that exploits thermodynamic energy balances to gently shuttle EVs to one fluid phase, while moving all other bodily fluid components to a different fluid phase, and the addition of a secondary approach to select for specific EV subpopulations. The specific objectives in this project are to 1) optimize an ATPS for specific subpopulations of EVs, and 2) integrate the ATPS into a microfluidic format for maximum EV partitioning.A Vancouver-based biotechnology company is already attracted to this project because of the project's potential impact in the area of biomedicine. The completion of this project will lead us to the position of being able to license the technology to potential commercial partners, and realize a new EV isolation and purification tool that has important utility in EV research, and makes liquid biopsies widely usable in cancer diagnosis and treatment monitoring applications.

NSERC的创新创意(I2I)基金将资助开发一种微流控平台技术，直接从体液(如全血和尿液)中分离和提纯细胞外小泡(EV)。这种微流控方法产生的EV浓度比目前的金标准超速离心法所能达到的浓度高出数倍。我们的方法结合了微流体的精确度和双水相系统(ATPS)流体的选择性分配能力，可以分离和纯化EV，重要的是，克服了超速离心法的关键限制--即EV浓度太低而无法应用、杂质共隔离和EV损坏。我们技术的关键创新是微流体和内部优化的ATPS的结合，该ATPS利用热力学能量平衡将电动汽车轻轻地穿梭到一个流体相，同时将所有其他身体流体成分移动到不同的流体相，并增加了一种辅助方法来选择特定的电动汽车亚群。该项目的具体目标是1)针对特定的电动汽车亚群优化ATP，以及2)将ATP集成到微流控格式以最大限度地分割电动汽车。由于该项目在生物医学领域的潜在影响，一家总部位于温哥华的生物技术公司已经被吸引到该项目中。该项目的完成将使我们能够将该技术授权给潜在的商业合作伙伴，并实现一种新的EV分离和纯化工具，该工具在EV研究中具有重要实用价值，并使液体活检在癌症诊断和治疗监测应用中广泛使用。